Sustained Release Medication
with GMP facility

In Apr 2018, Peptron established own manufacturing facility in Osong, Korea, which can produce over 48,000 vials of SR-exenatide per month. All manufacturing equipment and process are designed and installed under GMP guideline. To get appropriate GMP certification, preparation of related GMP regulatory pathway and application process are on-going.

Read more

CNS medication
with new mechanism

In 2014, Peptron has exclusively licensed in the NIH patents which allows only Peptron to develop exenatide as drug for neurodegenerative disorders and both NIH and Peptron have been collaborating additional research.

Read more

SmartDepot

SmartDepot™ is Peptron’s proprietary ultrasonic spray drying technology for the preparation of sustained release (SR) injectable microsphere formulation of drug. Recently, this long-acting technology has attracted the intense attention of global pharmaceutical companies since the costs for developing new medicines are soaring and patent expirations of many blockbuster drugs are just around the corner.

Read more